Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS: We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA. The study was designed as a noninferiority trial to show that the difference between the rates of event-free survival at 2 years in the two groups was not greater than 5%. RESULTS: Complete remission was achieved in all 77 patients in the ATRA-arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA-chemotherapy group (95%) (P=0.12). The median follow-up was 34.4 months. Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points; P<0.001 for noninferiority and P=0.02 for superiority of ATRA-arsenic trioxide). Overall survival was also better with ATRA-arsenic trioxide (P=0.02). As compared with ATRA-chemotherapy, ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity. CONCLUSIONS: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana contro le Leucemie and others; ClinicalTrials.gov number, NCT00482833.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Self-citationShen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
van Dongen, J., Macintyre, E., Gabert, J., Delabesse, E., Rossi, V, Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401592 · Cited by 1,169
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationUnited States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826 · cited 1×
“A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay,28,29 demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH),30 or evidence of a microspeck…”
Research works printed but not linked: 3
- Zhang P, 1996, Chin J Hematol, 17, 58
- Sanz MA, 2000, Blood, 96, 1247
- Grimwade D, 2000, Blood, 96, 1297
Cited by
Items 201–300 of 1,000
Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases
Wang, Q. Q., Jiang, Y. H., & Naranmandura, H. (2020) · Metallomics · doi:10.1039/c9mt00308h · Cited by 61
Acute leukemia in the time of COVID-19
Gavillet, M., Klappert, J. C., Spertini, O., & Blum, S. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106353 · Cited by 64
Patient-reported outcomes in acute myeloid leukemia: Where are we now?
Buckley, S. A., Kirtane, K., Walter, R. B., Lee, S. J., & Lyman, G. H. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.08.010 · Cited by 61
Classic and Variants APLs, as Viewed from a Therapy Response
Geoffroy, M., & de Thé, H. (2020) · Cancers · doi:10.3390/cancers12040967 · Cited by 62
Grimwade, D. J., & Freeman, S. D. (2014) · Hematology · doi:10.1182/asheducation-2014.1.222 · Cited by 60
IDH Inhibitors in AML—Promise and Pitfalls
McMurry, H. S., Fletcher, L. B., & Traer, E. A. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00619-3 · Cited by 60
Acute promyelocytic leukemia: preventing early complications and late toxicities
Abedin, S. M., & Altman, J. K. (2016) · Hematology · doi:10.1182/asheducation-2016.1.10 · Cited by 56
Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia
Salerno, L., Romeo, G., Modica, M. N., Amata, E., Sorrenti, V., Barbagallo, I. A., & Pittalà, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.031 · Cited by 57
Molecular remission as a therapeutic objective in acute promyelocytic leukemia
Cicconi, L., Fenaux, P., Kantarjian, H. M., Tallman, M. S., Sanz, M. Á., & Lo‐Coco, F. (2018) · Leukemia · doi:10.1038/s41375-018-0219-5 · Cited by 62
Self-citationTreatment of Acute Promyelocytic Leukemia in Adults
Osman, A. E. G., Anderson, J., Churpek, J. E., Christ, T. N., Curran, E. K., Godley, L. A., Liu, H., Thirman, M. J., Odenike, T., Stock, W., et al. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00328 · Cited by 56
Thrombo-hemorrhagic deaths in acute promyelocytic leukemia
Breccia, M., & Lo‐Coco, F. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50019-9 · Cited by 55
Self-citationZhan, T., & Boutros, M. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1117053 · Cited by 57
“A phase 3 clinical trial showed that combination of both substances is most likely superior to standard therapy and associated with less hematological toxicity, but higher hepatic toxicity (Lo-Coco et al., 2013).”
BackgroundLiu, T., Men, Q., Wu, G., Yu, C., Huang, Z., Liu, X., & Li, W. (2015) · Oncotarget · doi:10.18632/oncotarget.3505 · Cited by 54
“Clinically, all-trans retinoic acid (ATRA) alone or in combination with arsenic trioxide (ATO) treatment targets the RARα and induces terminal differentiation of APL blasts [9-12].”
BackgroundNoguera, N. I., Pelosi, E., Angelini, D. F., Piredda, M. L., Guerrera, G., Piras, E., Battistini, L., Massai, L., Berardi, A. C., Catalano, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15925 · Cited by 57
Self-citationRecurrent RARB Translocations in Acute Promyelocytic Leukemia Lacking RARA Translocation
Osumi, T., Tsujimoto, S., Tamura, M., Uchiyama, M., Nakabayashi, K., Okamura, K., Yoshida, M., Tomizawa, D., Watanabe, A., Takahashi, H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0840 · Cited by 54
“Recent clinical trials demonstrated that a combination of ATRA and ATO achieved excellent outcomes, with more than 90% event-free survival for typical APL with PML–RARA, even without conventional cytotoxic chemotherapy (4).”
BackgroundA phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma
Hanna, G. J., O’Neill, A., Cutler, J. M., Flynn, M., Vijaykumar, T., Clark, J. R., Wirth, L. J., Lorch, J. H., Park, J. C., Mito, J. K., et al. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105366 · Cited by 54
The cure of leukemia through the optimist's prism
Kantarjian, H. M., Jain, N., Garcia‐Manero, G., Welch, M. A., Ravandi, F., Wierda, W. G., & Jabbour, E. J. (2021) · Cancer · doi:10.1002/cncr.33933 · Cited by 54
Targeting IκappaB kinases for cancer therapy
Awasthee, N., Rai, V., Chava, S. P., Nallasamy, P., Kunnumakkara, A. B., Bishayee, A., Chauhan, S. C., Challagundla, K. B., & Gupta, S. C. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.007 · Cited by 57
“It is now used for the treatment of acute promyelocytic leukemia [95].”
BackgroundWang, Q. Q., Hua, H. Y., Naranmandura, H., & Zhu, H. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115299 · Cited by 55
Liu, X., Gu, Y., Bian, Y., Cai, D., Li, Y., Zhao, Y., Zhang, Z., Xue, M., & Zhang, L. (2021) · APOPTOSIS · doi:10.1007/s10495-020-01655-9 · Cited by 54
An Overview of Targeted Therapies in Acute Myeloid Leukemia
Turkalj, S., Radtke, F. A., & Vyas, P. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000914 · Cited by 58
“10,11 This approach highlighted the potential for differentiation therapy in leukemia 12 and demonstrated the importance of combining targeted therapies with synergistic mechanisms of action.”
Castillo, J. J., Mulkey, F. A., Geyer, S. M., Kolitz, J. E., Blum, W. G., Powell, B. L., George, S. L., Larson, R. A., & Stone, R. M. (2015) · American Journal of Hematology · doi:10.1002/ajh.24230 · Cited by 54
Lavallée, V., Chagraoui, J., MacRae, T., Marquis, M., Bonnefoy, A., Krošl, J., Lemieux, S., Marinier, A., Pabst, C., Rivard, G., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0069-1 · Cited by 52
Ushering in the next generation of precision trials for pediatric cancer
DuBois, S. G., Corson, L., Stegmaier, K., & Janeway, K. A. (2019) · Science · doi:10.1126/science.aaw4153 · Cited by 55
Short, N. J., & Ravandi, F. (2019) · Haematologica · doi:10.3324/haematol.2018.208454 · Cited by 58
“The link between MRD status and prognosis, as well as an effective salvage therapy for MRD-positive disease, makes acute promyelocytic leukemia a model for MRD-guided therapies, although it is unclear whether routine, universal monitoring is still required in the era of regimens capable of curing >95% of non-high-risk…”
BackgroundGill, H., Yung, Y., Chu, H.-T., Au, W., Yip, P.-K., Lee, E., Yim, R., Lee, P., Cheuk, D. K., Ha, S., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004789 · Cited by 52
Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly
Klepin, H. D. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.08.010 · Cited by 56
Bergamasco, M. D., Pereira, C. A. P., Arrais‐Rodrigues, C., Ferreira, D. B., Baiocchi, O. C. G., Kerbauy, F. R., Nucci, M., & Colombo, A. L. (2021) · Journal of Fungi · doi:10.3390/jof7080588 · Cited by 57
“The use of differentiating agents (retinoic acid, arsenic trioxide) in the induction remission of APL results in a lower incidence of gastrointestinal mucositis and shorter duration of neutropenia compared with a standard “7 + 3” induction regimen of AML [29,30].”
BackgroundShao, X., Chen, Y., Wang, W., Du, W., Zhang, X., Cai, M., Bing, S., Cao, J., Xu, X., Yang, B., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.020 · Cited by 56
Moving toward individualized target-based therapies in acute myeloid leukemia
Bazinet, A., & Kantarjian, H. M. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.11.004 · Cited by 66
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
Voso, M. T., Guarnera, L., Lehmann, S., Döhner, K., Döhner, H., Platzbecker, U., Russell, N. H., Dillon, R. J., Thomas, I., Ossenkoppele, G. J., et al. (2024) · Blood · doi:10.1182/blood.2024026186 · Cited by 61
Self-citationAdvances in treatment formulations for acute myeloid leukemia
Briot, T., Roger, E., Thépot, S., & Lagarce, F. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.040 · Cited by 58
“The combination of ATRA with ATO resulted in the first chemotherapy-free regimen for AML and has become the new standard for APL [19] with inferior toxicity compared with ATRA combined with chemotherapy [20,21].”
BackgroundSuper-enhancers complexes zoom in transcription in cancer
Wang, M., Chen, Q., Wang, S., Xie, H., Liu, J., Huang, R., Xiang, Y., Jiang, Y., Tian, D., & Bian, E. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02763-5 · Cited by 61
“Targeting oncogenic TFs in cancer, such as PMLRARA, has been shown to have significant therapeutic benefits when their application is practical [88].”
BackgroundChendamarai, E., Ganesan, S., Alex, A. A., Kamath, V., Nair, S. C., Nellickal, A. J., Arthur, N. B. J., Srivastava, V. M., Lakshmi, K. M., Viswabandya, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121912 · Cited by 51
Coltella, N., Valsecchi, R., Ponente, M., Ponzoni, M., & Bernardi, R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3022 · Cited by 49
“It has been demonstrated that newly diagnosed patients with APL may avoid treatment with cytotoxic chemotherapy and undergo less harmful combination treatments with ATRA andATO,which reach similar cure rates without triggering the long-term complications of chemotherapy (4, 29).”
BackgroundInfluentialIntrinsic and Stable Conjugation of Thiolated Mesoporous Silica Nanoparticles with Radioarsenic
Ellison, P. A., Chen, F., Goel, S., Barnhart, T. E., Nickles, R. J., DeJesus, O. T., & Cai, W. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b14049 · Cited by 50
Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress
Masciarelli, S., Capuano, E., Ottone, T., Divona, M., Panfilis, S. D., Banella, C., Noguera, N. I., Picardi, A., Fontemaggi, G., Blandino, G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.231 · Cited by 49
Self-citationMechanisms and management of coagulopathy in acute promyelocytic leukemia
David, S., & Mathews, V. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.01.041 · Cited by 51
Quintela-Fandiño, M., Morales, S. M., Cortés-Salgado, A., Manso, L., Apala, J. V., Muñoz, M., Cudós, A. G., Fortuny, J. S., Gión, M., López‐Alonso, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2023 · Cited by 50
Chen, Y., & Hu, J. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620719899818 · Cited by 49
The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML
Kahl, M., Brioli, A., Bens, M., Perner, F., Kresinsky, A., Schnetzke, U., Hinze, A., Sbirkov, Y., Stengel, S., Simonetti, G., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0581-y · Cited by 48
Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation
van Gils, N., Verhagen, H. J. M. P., & Smit, L. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.04.007 · Cited by 49
Zheng, H., Jiang, H., Hu, S., Liao, N., Shen, D., Tian, X., Hao, G., Jin, R., Li, J., Fang, Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03096 · Cited by 50
“0) 310(9)/L and 28 (2-211) 310(9)/L, respectively.”
ACUTE PROMYELOCYTIC LEUKEMIA (APL): COMPARISON BETWEEN CHILDREN AND ADULTS
Testi, A. M., & Lococo, F. (2014) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2014.032 · Cited by 48
Self-citationShen, Y., Fu, Y., Zhu, Y., Lou, Y., Gu, Z., Shi, J., Chen, B., Chen, C., Zhu, H., Hu, J., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.04.006 · Cited by 49
“ATRA plus chemotherapy (anthracyclines alone or with Ara-C) has been used as routine practice for treatment of APL in hematology/oncology centers worldwide (Degos et al., 1995; Avvisati et al., 1996; De Botton et al., 1998; Estey et al., 2005; Lo-Coco et al., 2013; Sanz et al., 2000).”
BackgroundMethodThe Impact of Flt3 Gene Mutations in Acute Promyelocytic Leukemia: A Meta-Analysis
Picharski, G. L., de Andrade, D. P., Fabro, A. L. M. R., Lenzi, L., Tonin, F. S., Ribeiro, R. C., & de Figueiredo, B. C. (2019) · Cancers · doi:10.3390/cancers11091311 · Cited by 51
“Patients with WBC count less than 10 × 109/L at diagnosis are currently treated with a combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which are associated with survival rates or more than 90% [9].”
BackgroundComprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing
Mack, E., Marquardt, A., Langer, D., Ross, P., Ultsch, A., Kiehl, M. G., Mack, H. I. D., Haferlach, T., Neubauer, A., & Brendel, C. A. (2018) · Haematologica · doi:10.3324/haematol.2018.194258 · Cited by 51
“AML-16 58 M2 BM 50% 60% 46,XX,t(8;21)(q22;q22) [6], 45,X,-X 2,053,046 1,629,435”
Retinoid receptor signaling and autophagy in acute promyelocytic leukemia
Orfali, N., McKenna, S. L., Cahill, M. R., Gudas, L. J., & Mongan, N. P. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.03.018 · Cited by 49
“This proteolysis is likely to be one of the integral mechanisms through which ATRA and ATO exert their clinically proven anti-leukemic efficacy in APL [101] (Fig.”
Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia
Zhu, H., Liu, Y., Jia, J., Qin, Y., Zhao, X.-S., & Lai, Y. (2018) · Blood · doi:10.1182/blood-2018-02-834051 · Cited by 47
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia
Lehmann‐Che, J., Bally, C., Letouzé, É., Berthier, C., Yuan, H., Jollivet, F., Adès, L., Cassinat, B., Hirsch, P., Pigneux, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04384-5 · Cited by 51
Predictors of early hemorrhage in acute promyelocytic leukemia
Naymagon, L., Moshier, E. L., Tremblay, D. A., & Mascarenhas, J. O. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1581187 · Cited by 47
How I treat acute myeloid leukemia with differentiation therapy
Issa, G. C., Stein, E. M., & Dinardo, C. D. (2024) · Blood · doi:10.1182/blood.2024024008 · Cited by 52
Lou, Y., Ma, Y., Suo, S., Ni, W., Wang, Y., Pan, H., Tong, H., Qian, W., Meng, H., Mai, W., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.05.016 · Cited by 46
Progress in Acute Myeloid Leukemia
Kadia, T. M., Ravandi, F., O'Brien, S. M., Cortes, J. E., & Kantarjian, H. M. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.08.006 · Cited by 52
Verhagen, H. J. M. P., Smit, M. A., Rutten, A. P., Denkers, F., Poddighe, P. J., Merle, P. A., Ossenkoppele, G. J., & Smit, L. (2015) · Blood · doi:10.1182/blood-2015-07-653840 · Cited by 47
Mendez, L., Posey, R. R., & Pandolfi, P. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01162 · Cited by 53
“The phenomenal success of this chemotherapy-free targeted combination therapy (111) was informed by genetic models providing insights into the underpinnings of resistance and response to ATRA and ATO (112).”
BackgroundDifferentiation of Cancer Stem Cells through Nanoparticle Surface Engineering
Geng, Y., Amante, J. J., Goel, H. L., Zhang, X., Walker, M. R., Luther, D. C., Mercurio, A. M., & Rotello, V. M. (2020) · ACS Nano · doi:10.1021/acsnano.0c05589 · Cited by 45
Sanford, D., Lo‐Coco, F., Sanz, M. Á., Bona, E. D., Coutre, S. E., Altman, J. K., Wetzler, M., Allen, S. L., Ravandi, F., Kantarjian, H. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13607 · Cited by 46
Self-citationTargeting fusions for improved outcomes in oncology treatment
Nikanjam, M., Okamura, R., Barkauskas, D. A., & Kurzrock, R. (2019) · Cancer · doi:10.1002/cncr.32649 · Cited by 48
Clinical challenges in de novo pediatric acute myeloid leukemia
Klein, K., de Haas, V., & Kaspers, G. J. L. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1428091 · Cited by 48
“Although in adults lower ED rates are reported with the combination of ATO-ATRA [67], this trend needs confirmation in pediatric trials.”
BackgroundAcute Leukemia: Diagnosis and Treatment
Blackburn, L. M., Bender, S., & Brown, S. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.150950 · Cited by 71
The genomics of acute myeloid leukemia in children
Conneely, S. E., & Rau, R. E. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09846-1 · Cited by 52
Management of Disseminated Intravascular Coagulation in Acute Leukemias
Cate, H. T., & Leader, A. (2021) · Hämostaseologie · doi:10.1055/a-1393-8302 · Cited by 46
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy
Li, T., Ma, R., Zhang, Y., Mo, H., Yang, X., Hu, S., Wang, L., Novakovic, V. A., Chen, H., Kou, J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0018-3 · Cited by 45
Gill, H., Kumana, C. R., Yim, R., Hwang, Y., Chan, T. S. Y., Yip, S., Lee, H. K. K., Mak, V., Lau, J. S. M., Chan, C., et al. (2019) · Cancer · doi:10.1002/cncr.32180 · Cited by 44
“Follow-up, median (range), mo 37 (13-82) 52 (14-77) <.”
Critical transition and reversion of tumorigenesis
Shin, D., & Cho, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00969-3 · Cited by 48
KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives
Guarnera, L., D’Addona, M., Bravo‐Pérez, C., & Visconte, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169023 · Cited by 50
“…mimicking the path of other successful predecessors among smart drugs, such as all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia [59] and FLT3 inhibitors for FLT3 mutant AML [60], leading to a change in the paradigms of the treatment and prognosis of the disease.”
BackgroundRedner, A., & Kessel, R. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801368-7.00019-3 · Cited by 44
Bravo, G. M., Huang, X., Jabbour, E. J., Borthakur, G. M., Dinardo, C. D., Pemmaraju, N., Cortes, J. E., Verstovšek, S., Kadia, T. M., Daver, N. G., et al. (2016) · Leukemia · doi:10.1038/leu.2016.303 · Cited by 44
S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer
Noye, T. M., Lokman, N. A., Oehler, M. K., & Ricciardelli, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124122 · Cited by 50
“ATRA is currently used as a primary treatment for patients with APL [61,62,105].”
BackgroundFLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias
Esnault, C., Rahmé, R., Rice, K. L., Berthier, C., Gaillard, C. M., Quentin, S., Maubert, A.-L., Kogan, S. C., & de Thé, H. (2019) · Blood · doi:10.1182/blood-2018-07-866095 · Cited by 48
“Combined RA/As treatment overcomes FLT3-ITD-triggered resistance Multiple clinical studies have now demonstrated the potency of the ATRA/arsenic combination, including in FLT3-mutant APLs.(44,45,64,65,79,82) We thus examined the effects of the ATRA/arsenic combination in our two APL models.”
Kwaan, H. C., Weiss, I. M., & Tallman, M. S. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1693478 · Cited by 44
RNF4—A Paradigm for SUMOylation‐Mediated Ubiquitination
Kumar, R., & Sabapathy, K. (2019) · PROTEOMICS · doi:10.1002/pmic.201900185 · Cited by 45
Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?
Hambley, B. C., Tomuleasa, C., & Ghiaur, G. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.722614 · Cited by 46
“For APL patients who survive the first 30 days, over 90% are cured of the disease (4, 5).”
BackgroundInfluentialDhokia, V., & Macip, S. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00754-z · Cited by 50
“A combination treatment of ATRA and arsenic trioxide (As2O3) can increase overall survival and complete remission in these patients when compared to ATRA alone [47].”
BackgroundDeregulated transcription factors in the emerging cancer hallmarks
Hasan, A., Khan, N. A., Shahab Uddin, M. S., Khan, A. Q., & Steinhoff, M. S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.12.001 · Cited by 48
Groups, O. B. O. T. I.-A. A. P. A. H., Sanz, M. Á., Montesinos, P., Kim, H. T., Ruiz-Argüelles, G. J., Undurraga, M. S., Uriarte, M., Martínez, L., Jácomo, R. H., Gutiérrez‐Aguirre, C. H., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2393-0 · Cited by 43
Self-citationDisruption of Mitotic Progression by Arsenic
States, J. C. (2015) · Biological Trace Element Research · doi:10.1007/s12011-015-0306-7 · Cited by 45
“ATO is an effective chemotherapeutic in combination with all trans retinoic acid (ATRA) for treating acute APL [20–22].”
Cannella, L., Caocci, G., Jacobs, M., Vignetti, M., Mandelli, F., & Efficace, F. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.07.012 · Cited by 43
Self-citationWang, H., Gong, S., Li, G., Yao, Y., Zheng, Y.-S., Lü, X., Wei, S., Qin, W., Liu, H.-B., Wang, M.-C., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00753-y · Cited by 47
“Leukocytosis was defined as a WBC count of more than 10 × 10(9)/L [16].”
BackgroundMethodBiomimetic nanoparticles for siRNA delivery in the treatment of leukaemia
Guo, J., Cahill, M. R., McKenna, S. L., & O’Driscoll, C. M. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.08.007 · Cited by 46
Cagnetta, A., Adamia, S., Acharya, C., Patrone, F., Miglino, M., Nencioni, A., Gobbi, M., & Cea, M. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.006 · Cited by 46
“Therefore, he identification of genetic features to predict response to treatent is crucial not only to guide but also to optimize the current herapeutic strategies available for CN-AML patients [2,6].”
BackgroundKäyser, S., Krzykalla, J., Elliott, M. A., Norsworthy, K. J., Gonzales, P. K., Hills, R. K., Baer, M. R., Ráčil, Z., Mayer, J., Novák, J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.92 · Cited by 43
Self-citationReal-life Outcomes on Acute Promyelocytic Leukemia in Brazil – Early Deaths Are Still a Problem
da Silva, W. F., da Rosa, L. I., Marquez, G. L., Bassolli, L., Tucunduva, L. T. C. D. M., Silveira, D. R., Buccheri, V., Bendit, I., Rego, E. M., Rocha, V., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.11.004 · Cited by 42
Perry, J. A., Seong, B. K. A., & Stegmaier, K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055710 · Cited by 42
“In the case of APL, patients are often successfully treated with ATO and ATRA, which induce both differentiation and apoptosis in leukemic cells (Lo-Coco et al. 2013).”
BackgroundThe Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias
Martelli, A. M., Paganelli, F., Chiarini, F., Evangelisti, C., & McCubrey, J. A. (2020) · Cancers · doi:10.3390/cancers12020333 · Cited by 48
Enasidenib and ivosidenib in AML
Martelli, M. P., Martino, G., Cardinali, V., Falini, B., Martinelli, G., & Cerchione, C. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.07024-x · Cited by 46
Johansson, B., & Harrison, C. J. (2015) · Wiley eBooks · doi:10.1002/9781118795569.ch6 · Cited by 44
Lou, Y., Ma, Y., Sun, J., Ye, X., Pan, H., Wang, Y., Qian, W., Meng, H., Mai, W., He, J., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2477-x · Cited by 42
“ducing the rates of relapse [26–29].”
Marchwicka, A., Cebrat, M., Sampath, P., ewski, Å. Å. ⁄., & Marcinkowska, E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00125 · Cited by 48
“The recent multicenter study, which compared the ATRA plus chemotherapy (idarubicin, mitoxantrone, methotrexate, and 6-mercaptopurine) with ATRA plus ATO in patients with APL, revealed that 2-year event-free survival rates were 97% in the ATRA–ATO group and 86% in the ATRA–chemotherapy group (61), showing that new par…”
BackgroundUeda, M., Lima, M. J. G. D., Caimi, P. F., Tomlinson, B. K., Little, J. A., Creger, R. J., Lazarus, H. M., & Cooper, B. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.104 · Cited by 41
Bolis, M., Garattini, E., Paroni, G., Zanetti, A., Kurosaki, M., Castrignanò, T., Garattini, S. K., Biancardi, F., Barzago, M. M., Gianni’, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw660 · Cited by 41
Minimal Residual Disease in Acute Myeloid Leukemia—Current Status and Future Perspectives
Käyser, S., Walter, R. B., Stock, W., & Schlenk, R. F. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0260-7 · Cited by 41
Self-citationAbla, O., Ribeiro, R. C., Testi, A. M., Montesinos, P., Creutzig, U., Sung, L., Giuseppe, G. D., Stephens, D., Feusner, J. H., Powell, B. L., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3042-6 · Cited by 41
Self-citationMercher, T., & Schwaller, J. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00401 · Cited by 48
“A phase III randomized multicenter trial demonstrated clinical efficacy and superiority of the combination of ATRA with As2O3 over ATRA and chemotherapy in adult patients (109).”
BackgroundGuarnera, L., Ottone, T., Fabiani, E., Divona, M., Savi, A., Travaglini, S., Falconi, G., Panetta, P., Rapanotti, M. C., & Voso, M. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871590 · Cited by 46
“org 4 The signal transducer and activator of transcription 5B (STAT5B) is a member of the STAT family transcription factors and mediates cell differentiation, proliferation, and survival signals induced by various cytokines and hormones (13, 117).”
BackgroundSelf-citation[Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2018)].
(2018) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2018.03.002 · Cited by 40
Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer
Lokman, N. A., Ho, R., Gunasegaran, K., Bonner, W. M., Oehler, M. K., & Ricciardelli, C. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1017-7 · Cited by 39
Application of vitamin D and vitamin D analogs in acute myelogenous leukemia
Cao, H. L., Xu, Y., de Necochea-Campion, R., Baylink, D. J., Payne, K. J., Tang, X., Ratanatharathorn, C., Ji, Y., Mirshahidi, S., & Chen, C.-S. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.01.007 · Cited by 41
Takeshita, A., Asou, N., Atsuta, Y., Sakura, T., Ueda, Y., Sawa, M., Dobashi, N., Taniguchi, Y., Suzuki, R., Nakagawa, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0233-7 · Cited by 41
Metadata
- Authors
- Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H. R., Cazzola, M., Melillo, L., Carella, A. M., Brandts, C. H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lübbert, M., Hänel, M., Schmitz, N., Link, H., Kropp, M. G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Döhner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Döhner, H., Ehninger, G., Schlenk, R. F., & Platzbecker, U.
- ORCID
- Avvisati, Giuseppe
- Vignetti, Marco
- Thiede, Christian
- Iacobelli, Simona
- Ferrara, Felicetto
- Fazi, Paola
- Cicconi, Laura
- Specchia, Giorgina
- Sica, Simona
- Fiedler, Walter
- Breccia, Massimo
- Salih, Helmut R.
- Cazzola, Mario
- Melillo, Lorella
- Carella, Angelo M.
- Brandts, Christian H.
- Hertenstein, Bernd
- Lübbert, Michael
- Hänel, Matthias
- Schmitz, Norbert
- Link, Hartmut
- Rambaldi, Alessandro
- Luppi, Mario
- Ciceri, Fabio
- Finizio, Olimpia
- Venditti, Adriano
- Döhner, Konstanze
- Ganser, Arnold
- Amadori, Sergio
- Döhner, Hartmut
- Ehninger, Gerhard
- Schlenk, Richard F.
- Platzbecker, Uwe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-11
- Volume
- 369
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2129338773
- Cited by
- 1,611
- References
- 42
- Citations by year
- 2026: 83 · 2025: 89 · 2024: 132 · 2023: 144 · 2022: 110 · 2021: 147 · 2020: 137 · 2019: 125 · 2018: 122 · 2017: 107 · 2016: 117 · 2015: 144 · 2014: 119 · 2013: 33
- FWCI
- 61.62
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- acute promyelocytic leukemia, all-trans retinoic acid, arsenic trioxide, idarubicin, induction therapy, consolidation therapy, maintenance therapy, event-free survival, overall survival, complete remission, hematologic toxicity, hepatotoxicity
- MeSH terms
- Arsenic Trioxide, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Arsenicals, Female, Humans, Male, Middle Aged, Neutropenia, Oxides, Thrombocytopenia, Tretinoin, Leukemia, Promyelocytic, Acute, Disease-Free Survival, Young Adult, Maintenance Chemotherapy, Induction Chemotherapy, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.